Chief operating officer at Bahl & Gaynor
Appears in 1 story
Portfolio manager commenting on trial results
Adults with obesity and type 2 diabetes who took Eli Lilly's experimental EloraTZP lost an average of 23.3% of their body weight over 48 weeks — well beyond the 14.8% lost by those on tirzepatide alone, the drug sold as Zepbound. The combination pairs tirzepatide, a dual GIP and GLP-1 receptor agonist, with eloralintide, a selective amylin receptor agonist, engaging three appetite-regulating hormone pathways at once.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
